Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Oct;60(10):2327-2339.
doi: 10.1111/trf.16005. Epub 2020 Aug 31.

Prevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2015 to 2019: The Transfusion-Transmissible Infections Monitoring System (TTIMS)

Whitney R Steele  1 , Roger Y Dodd  1 , Edward P Notari  1 , Meng Xu  1 , Diane Nelson  1 , Debra A Kessler  2 , Rita Reik  3 , Alan E Williams  4 , Brian Custer  5 , Susan L Stramer  1 ; Transfusion-Transmissible Infections Monitoring System (TTIMS)
Affiliations
Clinical Trial

Prevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2015 to 2019: The Transfusion-Transmissible Infections Monitoring System (TTIMS)

Whitney R Steele et al. Transfusion. 2020 Oct.

Abstract

Background: The Transfusion-Transmissible Infections Monitoring System (TTIMS) combines data from four US blood collection organizations including approximately 60% of all donations to monitor demographic and temporal trends in infectious disease markers and policy impacts.

Study design and methods: Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) consensus-positive definitions combined serology and nucleic acid testing results. These along with donor and donation characteristics were assembled into a single data set. Overall donation prevalence and demographic subsets were compared pre- and post-implementation of the 2015 change in men who have sex with men (MSM) deferral policy, among other prevalence comparisons.

Results: From October 2015 to September 2019, there were 712 HIV-, 1735 HBV-, and 5217 HCV-positive samples identified from approximately 27.5 million donations (>9.4 million donors). Prevalences per 100 000 donations were 2.6 (HIV), 6.3 (HBV), and 19.0 (HCV), and the highest for all three agents were in donations from first-time male donors. Two slight but significant increases in HIV prevalence were observed, both for comparisons of Year 1 (pre-MSM policy change) versus Year 4 (post-MSM policy change) for first-time males and first-time females; in contrast, similar comparisons demonstrated decreases in HCV prevalence (all donors and general trends for males and females). Except for HIV, prevalence increased with age; for all agents, prevalence was markedly higher in the south.

Conclusions: No major trends were observed over 4 years covering the MSM policy change from indefinite to a 12-month deferral, but ongoing monitoring is warranted. Demographic trends are consistent with those observed in other donor studies and community trends.

Keywords: HBV; HCV; HIV; MSM; blood safety; prevalence; transfusion-transmitted infections.

PubMed Disclaimer

References

REFERENCES

    1. US Food and Drug Administration. Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products-Guidance for Industry. Silver Spring, MD: US Food and Drug Administration, 2015.
    1. Custer B, Stramer SL, Glynn S, Williams AE, Anderson SA. Transfusion-transmissible infection monitoring system: a tool to monitor changes in blood safety. Transfusion. 2016;56:1499-1502.
    1. Dodd RY, Notari EP, Nelson D, et al. Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States. Transfusion. 2016;56:2781-2789.
    1. Dodd RY, Crowder LA, Haynes JM, Notari EP, Stramer SL, Steele WR. Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10-year trends in prevalence, incidence, and residual risk, 2007 to 2016. Transfus Med Rev. 2020;34(2):81-93.
    1. Estimated HIV incidence and prevalence in the United States, 2010-2016. HIV Surveillance Supplemental Report 2019; 24(1). Centers for Disease Control and Prevention Web site, http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Last reviewed June 08, 2020.

Publication types

LinkOut - more resources